# Ecopipam PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ecopipam

> The PDUFA target action date for ecopipam, sponsored by TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), is Q1 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the ecopipam PDUFA date?

The PDUFA target action date for ecopipam, sponsored by TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), is Q1 2027. Status: scheduled. Press release filed with the SEC (EX-99): "The U.S. FDA accepted the ecopipam New Drug Application (NDA) for review, advancing a potential first-in-class selective D1 receptor anti-agonist for Tourette syndrome in the pediatric population, with an action date expected in Q1 2027." Last confirmed November 3, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/ecopipam)

Source: Press release filed with the SEC (EX-99), accession 0001171843-26-007054, https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/pdufa/ecopipam#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ecopipam |
| Codes | EBS-101 |
| Sponsor | TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) https://sec-api.dev/companies/teva/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### Q1 2027: PDUFA date

- Status: scheduled. Date confidence: quarter.
- First seen 2026-11-03, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001171843-26-007054): "The U.S. FDA accepted the ecopipam New Drug Application (NDA) for review, advancing a potential first-in-class selective D1 receptor anti-agonist for Tourette syndrome in the pediatric population, with an action date expected in Q1 2027." https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ecopipam.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ecopipam PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ecopipam

```bibtex
@misc{secapidev_pdufa_ecopipam_20261116,
  title        = {Ecopipam PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ecopipam}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ecopipam_20261116","title":"Ecopipam PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ecopipam","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
